469
Views
6
CrossRef citations to date
0
Altmetric
Clinical Features - Review

Stepwise approach to continuous glucose monitoring interpretation for internists and family physicians

ORCID Icon & ORCID Icon
Pages 743-751 | Received 13 Apr 2022, Accepted 03 Aug 2022, Published online: 18 Aug 2022

References

  • Hood KK, DiMeglio LA, Riddle MC. Putting continuous glucose monitoring to work for people with type 1 diabetes. Diabetes Care. 2020 Jan;43(1):19–21.
  • Beck RW, Riddlesworth T, Ruedy K, et al. Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: the DIAMOND randomized clinical trial. JAMA. 2017 Jan 24;317(4):371–378.
  • Lind M, Polonsky W, Hirsch IB, et al. Continuous glucose monitoring vs conventional therapy for glycemic control in adults with type 1 diabetes treated with multiple daily insulin injections: the GOLD RANDOMIZED CLINICAL TRIAL. JAMA. 2017 Jan 24;317(4):379–387.
  • Polonsky WH, Hessler D, Ruedy KJ, et al. The impact of continuous glucose monitoring on markers of quality of life in adults with type 1 diabetes: further findings from the DIAMOND randomized clinical trial. Diabetes Care. 2017 Jun;40(6):736–741.
  • Beck RW, Riddlesworth TD, Ruedy K, et al. Continuous glucose monitoring versus usual care in patients with type 2 diabetes receiving multiple daily insulin injections: a randomized trial. Ann Intern Med. 2017 Sep 19;167(6):365–374.
  • Martens T, Beck RW, Bailey R, et al. Effect of continuous glucose monitoring on glycemic control in patients with type 2 diabetes treated with basal insulin: a randomized clinical trial. JAMA. 2021 Jun 8;325(22):2262–2272.
  • American Diabetes Association Professional Practice Committee. 9. Pharmacologic Approaches to Glycemic Treatment: standards of Medical Care in Diabetes-2022. Diabetes Care. 2022 Jan 1;45(Suppl 1):S125–S143.
  • Beck RW, Connor CG, Mullen DM, et al. The fallacy of average: how using HbA1c alone to assess glycemic control can be misleading. Diabetes Care. 2017 Aug;40(8):994–999.
  • Perlman JE, Gooley TA, McNulty B, et al. HbA1c and glucose management indicator discordance: a real-world analysis. Diabetes Technol Ther. 2021 Apr;23(4):253–258.
  • Centers for Disease Control and Prevention. National diabetes statistics report website. March 29, 2022. Available from: https://www.cdc.gov/diabetes/data/statistics-report/index.html
  • Lu H, Holt JB, Cheng YJ, et al. Population-based geographic access to endocrinologists in the United States, 2012. BMC Health Serv Res. 2015 Dec 7;15(1):541.
  • Tai-Seale M, McGuire TG, Zhang W. Time allocation in primary care office visits. Health Serv Res. 2007 Oct;42(5):1871–1894.
  • Battelino T, Danne T, Bergenstal RM, et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care. 2019 Aug;42(8):1593–1603.
  • Vigersky RA, McMahon C. The relationship of hemoglobin A1C to time-in-range in patients with diabetes. Diabetes Technol Ther. 2019 Feb;21(2):81–85.
  • Beck RW, Bergenstal RM, Cheng P, et al. The relationships between time in range, hyperglycemia metrics, and HbA1c. J Diabetes Sci Technol. 2019 Jul;13(4):614–626.
  • Lu J, Ma X, Zhou J, et al. Association of time in range, as assessed by continuous glucose monitoring, with diabetic retinopathy in type 2 diabetes. Diabetes Care. 2018 Nov;41(11):2370–2376.
  • Ranjan AG, Rosenlund SV, Hansen TW, et al. Improved time in range over 1 year is associated with reduced albuminuria in individuals with sensor-augmented insulin pump-treated type 1 diabetes. Diabetes Care. 2020 Nov;43(11):2882–2885.
  • Beck RW, Bergenstal RM, Riddlesworth TD, et al. Validation of time in range as an outcome measure for diabetes clinical trials. Diabetes Care. 2019 Mar;42(3):400–405.
  • Lu J, Wang C, Shen Y, et al. Time in range in relation to all-cause and cardiovascular mortality in patients with type 2 diabetes: a prospective cohort study. Diabetes Care. 2021 Feb;44(2):549–555.
  • Kroger J, Reichel A, Siegmund T, et al. Clinical recommendations for the use of the ambulatory glucose profile in diabetes care. J Diabetes Sci Technol. 2020 May;14(3):586–594.
  • Zisman A, Morales F, Stewart J, et al. BeAM value: an indicator of the need to initiate and intensify prandial therapy in patients with type 2 diabetes mellitus receiving basal insulin. BMJ Open Diabetes Res Care. 2016;4(1):e000171.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.